TNDM:NASDAQTandem Diabetes Care, Inc. Analysis
Data as of 2026-09-01 - not real-time
$21.28
Latest Price
9/10Risk
Risk Level: High
Executive Summary
At $21.28, Tandem Diabetes Care, Inc. shows no decisive moving-average alignment, leaving the trend neutral. Over a rolling month the price has gained 20.9%. Momentum indicators put RSI at 52.0 (neutral) with MACD reading bearish. Price has been bracketed by support at $17.07 and resistance at $24.81.
The shares look overvalued, trading on 124.7 times earnings above a sector average of 30.6. The average analyst target implies 34.9% above today's level. Revenue is growing at 5.8% on a -6.1% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 65.8%, a beta of 1.06 and a maximum drawdown of 54.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against sell longer out, with 6/10 conviction on the long call.
The shares look overvalued, trading on 124.7 times earnings above a sector average of 30.6. The average analyst target implies 34.9% above today's level. Revenue is growing at 5.8% on a -6.1% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 65.8%, a beta of 1.06 and a maximum drawdown of 54.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against sell longer out, with 6/10 conviction on the long call.
Top Market Events
Diabetes technology company Tandem Diabetes Care NASDAQ:TNDM in Q2 CY2026, with sales up 5.Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small...Seeking Alpha25dTandem Diabetes Care, Inc.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Trading above the 200-day average of 19.75
- MACD momentum is negative
- 30-day price change of +20.9%
Medium Term
1–3 yearsCautious
Model confidence: 4/10
Key Factors
- P/E of 124.7 versus sector average of 30.6
- Trading above the 200-day average of 19.75
- Analyst targets imply +34.9% versus the current price
Long Term
> 3 yearsCautious
Model confidence: 6/10
Key Factors
- P/E of 124.7 versus sector average of 30.6
- Negative profit margin of -6.1%
- Analyst targets imply +34.9% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth5.80%
Profit Margin-6.08%
P/E Ratio124.7
ROE-48.03%
ROA-2.65%
Debt/Equity566.96
P/B Ratio11.3
Op. Cash Flow$-5523000
Free Cash Flow$-43949124
Industry P/E30.6
Technical Analysis
TrendNeutral
RSI52.0
Support$17.07
Resistance$24.81
MA 20$22.10
MA 50$18.83
MA 200$19.75
MACDBearish
VolumeDecreasing
Fear & Greed Index92.25
Valuation
Target Price$28.70
Upside/Downside34.87%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.06
Volatility65.84%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.